AstraZeneca Reports the Results for Imfinzi in P-III Trial for the Treatment of Hepatocellular Carcinoma
Shots:
- The P-III (EMERALD-1) clinical trial evaluates the safety & efficacy of Imfinzi + transarterial chemoembolization (TACE) + bevacizumab vs TACE alone in patients (n=616) with hepatocellular carcinoma (HCC) eligible for embolization in 157 centers across 18 countries
- As per the results, the trial met the 1EP with a statistically significant & clinically meaningful improvement in PFS vs TACE alone. Moreover, the trial is under evaluation to assess the 2EPs of OS, ORR & patient-reported outcomes
- Imfinzi is human mAb that binds to the PD-L1 protein that blocks the interaction of PD-L1 with the PD-1 & CD80 proteins thereby neutralizing the tumor’s immune-evading mechanisms and releasing the inhibition of immune responses
Ref: Businesswire | Image: AstraZeneca
Related News:- BioCity Collaborated with AstraZeneca to Evaluate BC3402 + Imfinzi (durvalumab) for Advanced Hepatocellular Carcinoma in China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
